Long-term safety of Methotrexate in the treatment of rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Yazici, Y ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

Methotrexate; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; INFLIXIMAB; METHOTREXATE; PENICILLAMINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; ANAKINRA; PREDNISONE;

ADD ON THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HEALTH CARE PERSONNEL; HUMAN; HYPOALBUMINEMIA; INFECTION; LEUKOPENIA; LIVER CIRRHOSIS; LIVER ENZYME BLOOD LEVEL; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; LYMPHOMA; META ANALYSIS (TOPIC); NEOPLASM; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; FOLLOW UP; LEUKOCYTE COUNT; LIVER BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; RISK FACTOR; VALIDATION STUDY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; METHOTREXATE; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650527357     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. KREMER JM, ALARCON GS, LIGHTFOOT RW JR et al.: Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994;37:316-28.
2. YAZICI Y, ERKAN D, PAGET SA: Monitoring for methotrexate hepatic toxicity in rheumatoid arthritis patients: Is it time to update the guidelines? J Rheumatol 2002;29:1586-9.
3. SAAG KG, TENG GG, PATKAR NM et al.: American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic diseas e-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
4. YAZICI Y, ERKAN D, PAGET SA: Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events. Arthritis Rheum 2003;48:2769-72.
5. YAZICI Y, ERKAN D, HARRISON MJ, NIKOLOV NP, AGET SA: Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities. Clin Exp Rheumatol 2005;23:517-20.
6. ALETAHA D, SMOLEN JS: Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: Clinical evaluation and cost analysis. Arthritis Rheum 2002;47:181-8.
7. ALETAHA D, SMOLEN JS: The rheumatoid arthritis patient in the clinic: Comparing more than 1300 consecutive DMARD courses. Rheumatology 2002;41:1367-74.
8. YAZICI Y, SOKKA T, KAUTIAINEN H, SWEARINGEN C, KULMAN I, PINCUS T: Long-term safety of methotrexate in routine clinical care: Discontinuation is unusual and rarely due to laboratory abnormalities. Ann Rheum Dis 2005;64:207-11.
9. YAZICI Y, KRASNOKUTSKY S, BARNES JP, HINES PL, WANG J, ROSENBLATT L: Changing Patterns of Tumor Necrosis Factor Inhibitor Use in 9074 Patients with Rheumatoid Arthritis. J Rheumatol 2009;36:907-13.
10. HETLAND ML, CHRISTENSEN IJ, TARP U et al.: All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32.
11. SALLIOT C, VAN DER HEIJDE D: Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009;68:1100-4
12. KATCHAMART W, TRUDEAU J, PHUMETHUM V, BOMBARDIER C: Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2009;68:1105-12
13. PINCUS T, HUIZINGA TW, YAZICI Y: N-of-1 Trial of Low-dose Methotrexate and/or Prednisolone in Lieu of Anti-CCP, MRI, or Ultrasound, as First Option in Suspected Rheumatoid Arthritis? J Rheumatol 2007;34:250-2.
14. EMERY P, SALMON M: Early rheumatoid arthritis: Time to aim for remission? Ann Rheum Dis 1995;54:944-7.